

## **5th Annual Conference on Psychedelics and Psychedelic Medicine**

**Friday-Saturday, November 14-15, 2025**

**Live-Virtual**

**Boston, Massachusetts**

### **WELCOME**

On behalf of the Massachusetts General Hospital Psychiatry Academy and the Mass General Center for the Neuroscience of Psychedelics, we are proud to welcome you to the **5th Annual Conference on Psychedelics and Psychedelic Medicine**. You have our full attention over the next two days and we will do our very best to help you assess, treat, and manage your patients using the latest evidence to inform your decisions. Enjoy the program!

### **TARGET AUDIENCE**

The target audience for this event is mental health practitioners including psychiatrists, psychiatric nurse practitioners, social workers and clinical psychologists.

### **EVALUATION FORMS/CME/CEU CERTIFICATES**

Every participant needs to complete the activity evaluation online to claim CME/CEU credits for this course. Please refer to the **Evaluation and CME Information** document in this syllabus for more information. We strongly encourage you to complete the evaluation, even if you do not require a certificate. Your comments are important to us as we plan future programs. The link to claim credit is as follows:

<https://mghcme.org/Psychedelics2025>

### **QUESTIONS**

Opportunity for questions will be provided at the end of each module during the panel discussion. Please write your questions in the chat box on Zoom.

### **COPYRIGHT**

The course materials and PowerPoint presentations are copyright protected by Massachusetts General Hospital, Department of Psychiatry, Division of Postgraduate Education, the faculty members and the appropriate authors. Videotaping and audiotaping are not allowed. Thank you for your cooperation.

### **CONTACT INFORMATION**

For questions or comments, please contact Lynda Reid, MGH Psychiatry Academy member services at 866-644-7792 or [mghcme@mg.harvard.edu](mailto:mghcme@mg.harvard.edu).

### **LEARNING OBJECTIVES**

At the end of this educational activity, participants should be able to:

- Compare different models of psychedelic-assisted psychotherapy (e.g., psycholytic vs psychedelic)

- Identify the potential risks of psychedelic-assisted therapies.
- Identify the training and education programs and protocols for Psychedelic Assisted therapies.
- Explain the neuropsychopharmacology of classical psychedelics as well as atypical psychedelics such as ketamine and empathogens such as MDMA
- Identify the neuropsychopharmacology of classical psychedelics as well as atypical psychedelics such as ketamine and empathogens such as MDMA
- Identify hypotheses for mechanisms of action of psychedelics on the brain, based on recent neuroimaging studies
- Identify contemporary medico-cultural issues within psychedelic research.
- Critique contemporary medico-cultural issues within psychedelic research, including race-based structural biases and epistemic injustice
- Identify race-based structural biases and epistemic injustice in psychedelic research
- Assess potential applications of psychedelic-assisted therapy in extra-psychiatric fields, such as within palliative care and spirituality, as well as within medicine, such as for pain and immunomodulation
- Discuss the ethical considerations and frameworks necessary for conducting research with psychedelic substances.
- Analyze the current regulatory landscape for psychedelic therapies and its implications for clinical practice.

## ACCREDITATION



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Massachusetts General Hospital Institute of Health Professions.

MGH IHP is accredited by the ACCME to provide continuing medical education for physicians.

### Full Conference Attendance

#### ***Up to 10 AMA PRA Category 1 Credit™***

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Massachusetts General Hospital Institute of Health Professions is accredited by the ACCME to provide continuing medical education for physicians.

MGH Institute of Health Professions designates this live activity for a maximum of up to **10 AMA PRA Category 1 Credit™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

## PSYCHOLOGISTS



AMERICAN  
PSYCHOLOGICAL  
ASSOCIATION

The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education (CE) for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content. This offering meets the criteria for **10** Continuing Education (CE) credits for psychologists.

## REGISTERED NURSES

This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for up to **10** contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

## SOCIAL WORKERS



As a Jointly Accredited Organization, MGH Institute of Health Professions is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program.

Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. MGH Institute of Health Professions maintains responsibility for this course. Social workers completing this course receive **10** clock hours for continuing education credits.

**Other CE Licenses:** Other Providers can claim a Participation Certificate upon successful completion of this course. Participation Certificates will specify the title, location, type of activity, date of activity, and number of *AMA PRA Category 1 Credits™* associated with the activity. Providers should check with their regulatory agencies to determine ways in which *AMA PRA Category 1 Credits™* may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.

## AGENDA

### Day 1 – November 14, 2025

8:30-8:40 AM      **Welcome & Introduction**  
Franklin King, MD

### MODULE TOPIC 1: Foundations of Psychedelic Research and Practice

8:40–9:00 AM      **History & Pharmacology of Psychedelics Basics**  
Franklin King, MD

9:00-9:40 AM      **Keynote: State of Psychedelic Research in 2025**

David Yaden, PhD

**9:40-10:00 AM**      **Panel Discussion**  
Moderator: Jerrold Rosenbaum, MD  
Panelist: David Yaden, PhD

**10:00-10:15 AM**      **Break**

**MODULE TOPIC 2: The Neuroscience of Psychedelics**

**10:15-10:35 AM**      **Advancing the Cognitive Neuroscience of Psychedelics**  
Sharmin Ghaznavi, MD, PhD

**10:35-10:55 AM**      **Beyond the Trip: Classifying Psychedelic Compounds Through Neural Signatures**  
  
Alfred Kaye, MD, PhD

**10:55-11:25 AM**      **Panel Discussion**  
Moderator: Franklin King, MD  
Panelist: Sharmin Ghaznavi, MD, PhD; Alfred Kaye, MD, PhD

**MODULE TOPIC 3: Novel Entheogenic Compounds, Natural and Synthetic**

**11:25-11:45 AM**      **From Nature to Neuroscience: Novel Plant-Derived Psychedelics & Modeling Human Brain Plasticity with Neurons & Organoids**  
Stephen Haggarty, PhD

**11:45-12:05 PM**      **Synthetic Cathinones and PTSD: Investigating Novel Empathogenic Compounds Beyond Psychedelics**  
Ben Kelmendi, MD

**12:05-12:25 PM**      **Progress in Novel Entactogens as Therapeutics**  
Matthew Baggott, PhD

**12:25-12:55 PM**      **Panel Discussion**  
Moderator: Jerrold Rosenbaum, MD  
Panelists: Stephen Haggarty, PhD; Matthew Baggott, PhD; Ben Kelmendi, MD

**12:55-1:00 PM**      **Closing Remarks**  
Franklin King, MD

**Day 2 – November 15, 2025**

**9:00-9:05 AM**      **Welcome & Introduction**  
Franklin King, MD

#### **MODULE TOPIC 4: Clinical Frontiers & Ethical Tensions in Psychedelic Psychiatry**

- 9:05-9:25 AM**      **Psychedelics & Addictions, from Ketamine to Ibogaine**  
Joji Suzuki, MD
- 9:25-9:45 AM**      **Balancing Risk, Harm & Autonomy: An Ethical Perspective on Psychedelic Research**  
Brian Earp, PhD
- 9:45-10:05 AM**      **Psilocybin for Anorexia Nervosa**  
Natalie Gukasyan, MD
- 10:05-10:35 AM**      **Panel Discussion**  
Moderator: Franklin King, MD  
Panelists: Joji Suzuki, MD; Brian Earp, PhD; Natalie Gukasyan, MD
- 10:35-10:50 AM**      **Break**

#### **MODULE TOPIC 5: Implementation in Healthcare Settings: Insurance, Reimbursement & Medical Populations**

- 10:50-11:10 AM**      **Navigating Insurance & Reimbursement Pathways in Psychedelic Therapy**  
Brian Barnett, MD
- 11:10-11:30 AM**      **Ketamine in the General Hospital**  
Cristina Cusin, MD
- 11:30-11:50 AM**      **Psychedelics in Medical Populations: Perspective from a Study of Psilocybin-Assisted Therapy for Irritable Bowel Syndrome**  
Erin Mauney, MD
- 11:50-12:20 PM**      **Panel Discussion**  
Moderator: Franklin King, MD  
Panelists: Brian Barnett, MD; Cristina Cusin, MD; Erin Mauney, MD
- 12:20-1:20 PM**      **Lunch Break**

#### **MODULE TOPIC 6: Perspectives on Psychedelic-Assisted Therapy**

- 1:20-1:40 PM**      **On the Differences & Similarities of Working with Patients Using MDMA & Psilocybin**  
Kelley O'Donnell, MD, PhD
- 1:40-2:00 PM**      **Psychedelics in Death & Dying**  
Yvan Beaussant, MD
- 2:00-2:20 PM**      **Psychedelic-Assisted Therapy: Challenges of Capturing the Nuance**  
Roxanne Sholevar, MD

**2:20-2:50 PM**      **Panel Discussion**  
Moderator: Franklin King, MD  
Panelists: Kelley O'Donnell, MD, PhD; Yvan Beaussant, MD; Roxanne Sholevar, MD

**2:50-3:05 PM**      **Break**

**MODULE TOPIC 7: Rules of the Game: Redefining Evidence, Access & Legality in Psychedelic Science**

**3:05-3:25 PM**      **Policy & Law in Psychedelics: Navigating Evolving Frameworks**  
Allison Hoots, JD

**3:25-3:45 PM**      **Laboratory of the Future? Australia's prescription psychedelic roll out and other innovations in the Land of Oz**  
Paul Liknaitzky, PhD

**3:45-4:05 PM**      **Challenges of Placebo Control in Psychedelic RCTs**  
Balázs Szigeti, PhD

**4:05-4:35 PM**      **Panel Discussion**  
Moderator: Franklin King, MD  
Panelists: Allison Hoots, JD; Paul Liknaitzky, PhD; Balázs Szigeti, PhD

**4:35-4:45 PM**      **Closing Remarks**  
Franklin King, MD

**FACULTY**

**PLANNERS & COURSE DIRECTORS**

**Franklin King, MD (*Course Director*)**

Director, Training and Education, Center for Neuroscience of Psychedelics, Massachusetts General Hospital  
Instructor in Psychiatry, Harvard Medical School

-----  
**David H. Rubin, MD (*Planner/COI Reviewer*)**

Director, Division of Professional and Public Education, MGH  
Executive Director, MGH Psychiatry Academy and MGH *Visiting*, MGH  
Assistant Professor, Harvard Medical School

**Susan Sprich, PhD (*Psychologist Reviewer*)**

Assistant Professor, Harvard Medical School  
Director of Psychology Training  
Clinical Director of Psychology  
Director, Postgraduate Psychology Education, MGH Psychiatry Academy

Department of Psychiatry, Massachusetts General Hospital

**Jane Pimental, MPH (*Planner*)**

Director, Division of Professional and Public Education  
Managing Director, Massachusetts General Hospital Psychiatry Academy  
Massachusetts General Hospital

**Angela Alves, LICSW (*Social Worker Content Reviewer*)**

**Shuhan He, MD (*CME Content Reviewer*)**

**Jane Davis, DNP, CRNP (*Nurse Content Reviewer*)**

**SPEAKERS**

**Matthew Baggott, PhD**

CEO Tactogen

**Brian Barnett, MD**

Brian Barnett, MD  
Assistant Professor of Psychiatry  
Cleveland Clinic Department of Psychiatry and Psychology

**Yvan Beaussant, MD, MSc**

Instructor, Department of Psychosocial Oncology and Palliative Care  
Dana-Farber Cancer Institute  
Harvard Medical School  
Clinician investigator, Care Dimensions

**Cristina Cusin, MD**

Depression Clinical and Research Program  
Director, Ketamine Clinic  
Massachusetts General Hospital  
Associate Professor in Psychiatry  
Harvard Medical School

**Assistant Professor Brian D. Earp**

National University of Singapore

**Sharmin Ghaznavi, MD, PhD**

Associate Director, Center for the Neuroscience of Psychedelics, Psychiatry  
Director of Cognitive Neuroscience, Center for the Neuroscience of Psychedelics, Psychiatry  
Psychiatrist, Dauten Family Center for Bipolar Treatment Innovation

**Natalie Gukasyan, MD**

Assistant Professor  
Columbia University Medical Center, Dept of Psychiatry  
New York State Psychiatric Institute

**Stephen J. Haggarty, PhD**

Director, Chemical Neurobiology Laboratory  
Co-Director, MGH Precision Therapeutics Unit  
Scientific Director of Neurobiology, MGH Center  
for the Neuroscience of Psychedelics  
Stuart & Suzanne Steele Research Scholar  
Associate Professor of Neurology, Harvard Medical School

**Allison M. Hoots, Esq.**

Principal Attorney  
Hoots Law Practice PLLC

**Alfred Kaye, MD, PhD**

Assistant Professor  
Department of Psychiatry  
Yale University School of Medicine

**Benjamin Kelmendi, MD**

Assistant Professor  
Yale University, Department of Psychiatry

**Paul Liknaitzky, PhD**

Head, Clinical Psychedelic Lab  
Director, Monash Psychedelic Education Program  
Dept of Psychiatry, School of Clinical Sciences  
Monash University

Adjunct Senior Research Fellow  
School of Psychological Sciences, Monash University  
Dept of Psychiatry, University of Melbourne  
Centre for Mental Health, Swinburne University

**Erin Mauney MD**

Pediatric Gastroenterology, Hepatology, and Nutrition Fellow  
Massachusetts General Hospital

**Kelley O'Donnell, MD, PhD**

Assistant Professor of Psychiatry, NYU Grossman School of Medicine  
Director of Clinical Training, NYU Langone Center for Psychedelic Medicine

**Jerrold F. Rosenbaum, MD**

Psychiatrist-in-Chief Emeritus  
Director, Center for the Neuroscience of Psychedelics  
Massachusetts General Hospital  
Stanley Cobb Professor of Psychiatry, Harvard Medical School

**Roxanne Sholevar, MD**



Staff Psychiatrist, Dana Farber Cancer Institute  
Instructor in Psychiatry, Harvard Medical School

**Joji Suzuki, MD**

Joji Suzuki MD, FACLP

Division of Addiction Treatment and Prevention AMC Psychiatry Department, Mass General Brigham  
Program Director, Brigham and Women's Hospital Addiction Medicine Fellowship Program  
Associate Professor of Psychiatry, Harvard Medical School

**Balázs Szigeti, PhD**

Translational Psychedelic Research Program  
University of California San Francisco (UCSF)  
Center for Psychedelic Research  
Imperial College London

**David B. Yaden, PhD**

Associate Professor  
Griffiths Professor of Psychedelic Research  
Center for Psychedelic and Consciousness Research  
Department of Psychiatry and Behavioral Sciences  
Johns Hopkins University School of Medicine

**FACULTY DISCLOSURE STATEMENTS**

In accord with the disclosure policy of MGH Institute of Health Professions as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below:

**Commercial Interest**

The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit [www.accme.org](http://www.accme.org).

**Financial relationships**

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

**Relevant financial relationships**

ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or

increase the value of the relationship. The ACCME defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

### **Conflict of Interest**

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

**The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients:**

### **Speakers & Planners:**

<b>Matthew Baggott, PhD</b>	Tactogen Inc	CEO and Co-founder, Compensation and salary
<b>Brian Barnett, MD</b>	Abbott, Compass Pathways, MindMed and Reunion Neuroscience  AbbVie, CB Therapeutics, Janssen, Cerebral, EBSCO, Livanova	Research funding, PI  Personal Fee, Advisory Board/Consultant
<b>Yvan Beaussant, MD</b>	Runion Neuroscience Inc	Consult Fee
<b>Cristina Cusin, MD</b>	Compass, Clexio, Janssen, Boehringer Ingelheim,  Janssen, Livanova	Consult Fee, Advisory Board Speaker  Research Funding, Researcher
<b>Natalie Gukasyan, MD</b>	Maps	Speaker and program committee member
<b>Stephen Haggarty, PhD</b>	Souvien Therapeutics Proximity Therapeutics Sensorium Therapeutics 4M Therapeutics Psy Therapeutics Vesigen Therapeutics Entheos Labs Ilios Therapeutics Biohaven Pharmaceuticals Alzheimer's' Drug Discovery Foundation Fondazione Carpilo	Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Equity, Consultant, Scientific Advisory Board Sponsored Research Support at MGH; Consultant, Scientific Advisory Board Consultant, Scientific Advisory Board Consultant, Scientific Advisory Board Honorarium, Scientific Advisory Board Honorarium, Scientific Advisory Board Sponsored Research Support at MGH

	Lexicon Therapeutics Compass Pathways atai Life Sciences JW Pharmaceuticals Stealth Biotherapeutics, Birdwood Therapeutics	Sponsored Research Support at MGH Sponsored Research Support at MGH Sponsored Research Support at MGH Sponsored Research Support at MGH Scientific Advisory Board
<b>Alfred Kaye, MD</b>	Freedom Biosciences, Transcend Therapeutics	Research Funding
<b>Franklin King, MD</b>	Compass Pathways, Cybin, Apex Labs	Stock Owner, SAB
<b>Paul Liknaitzky, PhD</b>	Incannex healthcare, multidisciplinary assoc for psychedelic studies, Beckley Psytech, Cybin	Research Grant, PI
<b>Erin Mauney, MD</b>	Tryp Pharmaceuticals	Research Support
<b>Kelley O'Donnell, MD, PhD</b>	Lykos Therapeutics	Received compensation for participation in the FDA Advisory Committee meeting; also have received payments as a contractor to train therapists in MDMA-assisted therapy
<b>Jerrold Rosenbaum, MD</b>	Entheos Labs Psy Therapeutics Sensorium Therapeutics Terran Neuroscience Reunion Cerebral Inc	Equity, Fee Co-Funder, BOD SAB
<b>Susan Sprich, PhD (<i>Psychologist Reviewer</i>)</b>	Oxford University Press  Springer  Association for Behavioral Cognitive Therapies (ABCT)	Royalties (for co-authoring treatment manual and client workbook)  Royalties (for editing book)  Honorarium
<b>Joji Suzuki, MD</b>	Braeburn	Support for clinical trail, NIH funded trial
<b>David Yaden, PhD</b>	Integrative Psychiatry Institute, Soneria	Speaker fee, consult fee

**All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.**